Articles published by RIBOMIC Inc.

RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older

October 07, 2025

From RIBOMIC Inc.

Via Business Wire

RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort

November 05, 2024

From RIBOMIC Inc.

Via Business Wire

RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study

August 03, 2024

From RIBOMIC Inc.

Via Business Wire

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)

December 05, 2023

From RIBOMIC Inc.

Via Business Wire

RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration

March 23, 2022

From RIBOMIC Inc.

Via Business Wire

RIBOMIC Announces Preliminary Topline Data From Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration

December 28, 2021

From RIBOMIC Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by RIBOMIC Inc.

Starting at $3.75/week.

Subscribe Today